TomoHD™ radiation therapy system selected by UCSF Medical Center

Posted on May 04, 2011

Premier hospital to become first using TomoTherapy® technology in San Francisco

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that University of California, San Francisco (UCSF) Medical Center has purchased a TomoTherapy® TomoHD™ treatment system. Upon installation later this year, UCSF Medical Center will become the first treatment center using the TomoTherapy treatment platform in San Francisco. UCSF Medical Center ranks among the nation’s top 10 premier hospitals according to U.S. News & World Report’s 2010-11 America’s Best Hospitals survey.

“At UCSF, we are on a mission to provide the optimal treatment for every cancer case we treat,” said Dr. Mack Roach, professor, Radiation Oncology and Urology at UCSF. “Our state-of-the-art arsenal of radiation therapy solutions helps us ensure that our patients have access to the very best, and most appropriate, treatment available anywhere in the world.”

The TomoHD system enables clinicians to accurately and efficiently treat tumors throughout the body with advanced image-guided, intensity-modulated radiation therapy (IG-IMRT) capabilities. The system’s integrated imaging and treatment delivery capabilities provide an improved workflow for treating large field tumors, as well as prostate and head and neck cancers, among others.

“We are very pleased to offer cutting-edge radiation therapy solutions to patients,” said Fred Robertson, M.D., TomoTherapy’s president and CEO. “Adoption of the TomoHD treatment system provides clinicians with a flexible and efficient option for delivering high quality treatments to a wide range of tumors.”

This page was printed from OSL Web site at